Navigation Links
New drug prevents spread of human prostate cancer cells
Date:4/3/2012

CHICAGO --- A new drug developed by Northwestern Medicine scientists prevented human prostate cancer cells from spreading to other tissues without any toxic effects to normal cells or tissues. The drug turns off the "go" switch in the cancer cells and immobilizes them.

Prostate cancer is the second-leading cause of cancer death in North American males. Death is mainly caused by metastasis, prostate cancer cells moving out of prostate tissue and spreading to other organs.

"This is an extremely promising new therapeutic that locks down aggressive prostate cancer cells so they don't move," said Raymond Bergan, M.D., director of experimental therapeutics for the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. "The spread of prostate cancer is what kills men. Cancer cells have a switch that tells them to keep moving all the time. This drug turns it off."

The drug works by binding to and disabling proteins in the cancer cell that instruct it to move, said Bergan, a professor of medicine at Northwestern's Feinberg School of Medicine and a physician at Northwestern Memorial Hospital.

The research was presented April 3 at the American Association for Cancer Research Annual Meeting 2012 in Chicago by Li Xu, a research assistant professor of medicine at the Feinberg School. She helped develop the drug, along with Karl Scheidt, an associate professor of chemistry at the Weinberg College of Arts and Sciences.

In the study, Northwestern researchers transplanted aggressive human prostate cancer cells into mice prostate tissue and fed the mice with the new drug for five weeks. The drug inhibited movement of the cells and prevented them from metastasizing to the lung, one of the tissues to which prostate cancer spreads in men.

Xu said she conducted extensive toxicity studies, including on normal human cells, and found that the drug, called KBU2046, is nontoxic and does not cause any harmful effects.

"We envision that this drug, if shown to be effective in clinical trials, could be used to treat men diagnosed with prostate cancer, so they wouldn't need more aggressive procedures," Bergan said. "Or, the drug could augment the effectiveness of surgery and radiation."

Bergan hopes to test the drug in a clinical trial.


'/>"/>
Contact: Marla Paul
Marla-Paul@northwestern.edu
312-503-8928
Northwestern University
Source:Eurekalert

Related medicine news :

1. Colonoscopy prevents deaths from colon cancer
2. Dirt prevents allergy
3. Drug prevents bone loss side effects of breast cancer medication
4. Knockout of protein prevents colon tumor formation in mice
5. Marijuana administration after a traumatic experience prevents post-traumatic stress symptoms
6. Adding a stent during minimally invasive surgery to repair aneurysms prevents recurrence
7. Tai Chi Prevents Falls, Boosts Mental Health in Seniors: Study
8. UNC-led study shows early treatment with antiretroviral therapy prevents HIV transmission
9. Tobacco-derived compound prevents memory loss in Alzheimers disease mice
10. Early infusion of donor T cells prevents graft versus host disease in blood cancer patients
11. Tomatoes found to contain nutrient which prevents vascular diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... The Avamere Family ... – Avamere Transitional Care of Puget Sound ; located at 630 S ... center will provide patients recovering from illness or injury with intensive skilled nursing ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... Researchers at ... on the growing brains of young athletes. Over the course of three years, researchers ... through unique mouth guards. The mouth guards, equipped with special sensors, will track the ...
(Date:12/5/2016)... Fla (PRWEB) , ... December 05, 2016 , ... ... as Keynote speaker for the 21st Annual International Congress on Hematologic Malignancies®: Focus ... announcement, PER® president, Phil Talamo said, “We are honored to have Amy E. ...
(Date:12/5/2016)... ... December 05, 2016 , ... Dr. Barry M. Weintraub, one of New York ... participated in the 36th Annual Cutting Edge Aesthetic Symposium at the Waldorf Astoria in ... that perfect, yet natural-looking, nose. Dr. Weintraub, who is world-renowned for his expertise in ...
(Date:12/5/2016)... and MALVERN, PA (PRWEB) , ... ... ... Supplies Management ("CSM"), a Great Point Partners ("GPP") portfolio company, today announced ... – Clinical Supplies ("TCS"). TCS was previously a subsidiary of Chiltern ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Sanovas, Inc., a life science asset holding ... its wholly owned subsidiary, Intubation Science, Inc., and its LightSpeed ... - http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... Sanovas, Inc. ... There are over 40 million Endotracheal Intubations performed ...
(Date:12/5/2016)... 2016  CVS Health, the nation,s largest pharmacy innovation ... score of 100 percent on the Corporate Equality Index ... an annual national benchmarking survey and report on corporate ... the Human Rights Campaign Foundation. "Our ... colleagues, customers and suppliers bring to CVS Health," said ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 /PRNewswire/ ... announced preliminary safety and efficacy data from a ... selective MDM2 inhibitor, suggesting that DS-3032 may be ... acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome ... of the phase 1 study of DS-3032 were presented ...
Breaking Medicine Technology: